Publicaciones (93) Publicaciones de ELISA LUÑO FERNANDEZ

2020

  1. miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk

    Leukemia, Vol. 34, Núm. 10, pp. 2648-2659

2019

  1. Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy

    Leukemia and Lymphoma, Vol. 60, Núm. 5, pp. 1146-1155

2018

  1. Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries

    British Journal of Haematology, Vol. 181, Núm. 3, pp. 350-359

  2. Characterizing patients with multiple chromosomal aberrations detected by FISH in chronic lymphocytic leukemia

    Leukemia and Lymphoma, Vol. 59, Núm. 3, pp. 633-642

  3. Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia

    British Journal of Haematology

  4. Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significance

    Genes Chromosomes and Cancer, Vol. 57, Núm. 11, pp. 547-556

  5. Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes

    Blood Advances, Vol. 2, Núm. 16, pp. 2079-2089

  6. Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: A European LeukemiaNet study

    Leukemia, Vol. 32, Núm. 6, pp. 1380-1392

  7. Inhibition of flt3 and pim kinases by ec-70124 exerts potent activity in preclinical models of acute myeloid leukemia

    Molecular Cancer Therapeutics, Vol. 17, Núm. 3, pp. 614-624

  8. Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS

    Leukemia Research, Vol. 67, pp. 21-26

  9. Twelve years of experience with miglustat in the treatment of type 1 Gaucher disease: The Spanish ZAGAL project

    Blood Cells, Molecules, and Diseases, Vol. 68, pp. 173-179

2017

  1. Chronic lymphocytic leukemia with isochromosome 17q: An aggressive subgroup associated with TP53 mutations and complex karyotypes

    Cancer Letters, Vol. 409, pp. 42-48

  2. Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group

    Leukemia Research, Vol. 63, pp. 85-89

  3. Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R)

    American Journal of Hematology, Vol. 92, Núm. 7, pp. 614-621

  4. Excess mortality in the myelodysplastic syndromes

    American Journal of Hematology, Vol. 92, Núm. 2, pp. 149-154

  5. Impact of anaemia on health-related quality of life and cardiac remodelling in patients with lower risk myelodysplastic syndromes. Results of GlobQoL study

    European Journal of Cancer Care, Vol. 26, Núm. 6

  6. Monosomal karyotype in chronic lymphocytic leukemia: Association with clinical and biological features and potential prognostic significance

    American Journal of Hematology

  7. Multidimensional assessment of patient condition and mutational analysis in peripheral blood, as tools to improve outcome prediction in myelodysplastic syndromes: A prospective study of the Spanish MDS group

    American Journal of Hematology, Vol. 92, Núm. 9, pp. E534-E541

  8. Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions

    Oncotarget, Vol. 8, Núm. 33, pp. 54297-54303

2016

  1. Additional trisomies amongst patients with chronic lymphocytic leukemia carrying trisomy 12: The accompanying chromosome makes a difference

    Haematologica